John Feller, Chief Medical Officer at HaloDx, describes the first in human use of the Vaccinia virus inactivated by adult mesenchymal stem cells as a targeted oncolytic therapy in prostate cancer at the 12th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer held in Washington D.C. on Feb 2020,
